www.tickerreport.com ·
omeros q1 earnings call highlights
Topic context
This topic has been covered 407547 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedOmeros Corporation's Q1 2026 earnings highlight the commercial launch of YARTEMLEA for TA-TMA, a niche but high-value orphan drug. Revenue is early-stage with 30 accounts; the drug's pricing and adoption trajectory will determine margin expansion. The company's cash position supports ongoing commercialization. No supply chain or scarcity issues reported; impact is company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Omeros Q1 2026 net income $56.1M ($0.78/share) from YARTEMLEA sales.
- YARTEMLEA gross revenue $11.1M in Q1, initial shipments started January 2026.
- 30 unique accounts ordered YARTEMLEA by March 31; 60% of top 10 transplant centers approved.
- Cash and investments $135.3M at quarter end.
- Higher Q2 operating expenses expected due to launch activities.
YARTEMLEA account expansion could drive revenue growth over 2-4 weeks, with expected sales increase of 5-10% qoq.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
finance.yahoo.com
logicmark inc q1 2026 earnings 212238423
nwaonline.com
warsh okd by us senate as fed leader
livemint.com